Rhenman & Partners Asset Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Rhenman & Partners Asset Management’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-35,000	Closed	-$5.92M	–	98
2023 Q3	$5.92M	Hold	35,000	–	–	0.64%	45
2023 Q2	$7.59M	Sell	35,000 -2,000	-5%	-$428K	0.8%	41
2023 Q1	$6.67M	Buy	37,000 +7,000	+23%	+$1.34M	0.73%	46
2022 Q4	$5.89M	Buy	30,000 +10,000	+50%	+$2.14M	0.62%	53
2022 Q3	$4.39M	Buy	+20,000	New	+$4.05M	0.46%	62

Other funds holding KRTX

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Rhenman & Partners Asset Management's KRTX Position: Q4 2023 in Review

Rhenman & Partners Asset Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q4 2023, closing a stake of 35,000 shares — an estimated $5.92M sold.

Rhenman & Partners Asset Management first reported a position in KRTX in Q3 2022 and held it in 5 quarters. The position peaked at $7.59M in Q2 2023. 328 funds tracked by Wall St. Rank hold KRTX as of Q4 2023.

Rhenman & Partners Asset Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Rhenman & Partners Asset Management sold 35,000 Karuna Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $5.92M.
Rhenman & Partners Asset Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2022 and held it in 5 quarters.
Rhenman & Partners Asset Management's Karuna Therapeutics, Inc. Common Stock position peaked at $7.59M in Q2 2023.
328 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.